Alerts
China’s PD-1/VEGF Bet Challenges the Lung Cancer Backbone
HARMONi-6 showed an overall survival advantage for ivonescimab plus chemotherapy over PD-1 plus chemotherapy in first-line squamous NSCLC, putting China-origin oncology innovation directly into the global standard-of-care debate.
Huntington’s Disease Gets an Oral Target-Engagement Signal
A New CELMoD Raises the Bar in Relapsed Myeloma
IPM Alliance launches at the World Health Assembly in Geneva
Regulators Start Writing the Rules for AI-Driven Medicines
FDA Puts AI Inside the Evidence Machine
AI Diagnosis Has Entered the Access Debate
Lenacapavir Turns HIV Prevention Into an Access Stress Test
WHO’s AMR Plan Turns Access Into Preparedness
Geographic Atrophy Forces Europe to Define Meaningful Vision Benefit
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.